Office-use compounding in Montana

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

The phrase does not appear in Montana law at allHigh confidence

We searched the whole corpus of Montana pharmacy statutes and board rules for "office use", "office-use" and "office stock", case-insensitively. There are no occurrences in any Montana statute or rule. The only hits anywhere in the material are in copies of the federal statute held for cross-reference. That is a measured absence, not an unread gap.

The definition of compounding is disjunctive, and that is the findingHigh confidence

A patient-specific prescription drug order is limb (a) of five alternatives, not the gateway to all of them. Limb (d) is preparation based on routine, regularly observed prescribing patterns, and it carries no quantity ceiling, no percentage and no requirement of a prior order history. Limb (e) defines compounding by reference to the other party being an FDA-registered outsourcing facility.

Montana defines its own compounding partly by another party’s federal statusHigh confidence

Limb (e) is unusual and worth noticing: the state definition of compounding turns, for that limb, on a facility being registered as an outsourcing facility with the FDA. State permission and federal exemption are still separate questions everywhere — but Montana is the place where the state text reaches across into the federal register to describe its own subject matter.

The only office-use words available in Montana are federal, and a 503B cannot use themHigh confidence

Montana has no home-grown volume provision. It excludes from wholesale distribution "the exclusions listed in section 353(e)(4)" of the federal Drug Supply Chain Security Act, and one of those federal exclusions is the distribution of minimal quantities by a licensed retail pharmacy to a licensed practitioner for office use. Two consequences follow that readers routinely miss: that limb is available only to a licensed retail pharmacy, so an outsourcing facility cannot reach it; and the federal five per cent rule for registrants is a different provision that Montana has not adopted at all.

There is one substantive compounding rule and it is sterile-onlyHigh confidence

The board’s sterile products rule is the only substantive compounding rule in its book — there is no non-sterile compounding rule. Its caps are about batch and environment rather than about supply: no more than three sterile ingredients, products, components and devices in a preparation, and batch preparation not exceeding eight compounded sterile preparations. Its labelling requirement presupposes a named patient, as does the general prescription labelling rule beside it, so neither contemplates office stock.

A live rulemaking would close the silence, and it has not taken effectHigh confidence

The Board has proposed rules that would impose a patient-specific prescription requirement on both sterile and non-sterile compounding and create a new rule requiring an outsourcing facility shipping to a prescriber for administration or dispensing to hold a wholesale drug distributor licence. The comment period closed on 21 August 2026. As at the review date the sterile products rule still carries its pre-amendment title and status in the state’s own rules library, and the Board’s rule-notices page still publishes the proposal with no adoption notice beside it — so the proposal has not taken effect.Not taken effect is not the same as rejected. Anyone relying on Montana’s current position should re-check this before acting, because it is the single change most likely to move this page.

The practitioner exemption is qualified, and by more than it first appearsHigh confidence

The pharmacy chapter does not prevent a medical practitioner from compounding or using drugs in their own practice. But the exemption opens "Subject to 37-2-104, 37-7-401, and 37-7-402", and the first of those is the practitioner-dispensing registration section. A reader who quotes the exemption without its opening words has quoted a wider exemption than Montana enacted.

Controlled substances split sharply from everything elseHigh confidence

For non-controlled drugs a practitioner may dispense on registration. For controlled substances the statute bars a medical practitioner from dispensing at all unless they are engaged in the practice of pharmacy. Administration is treated differently again: the administration of a unit dose of a drug to a patient sits outside the registration requirement, which is the distinction that matters most to a practice holding office stock to inject rather than to hand over.

Montana at a glance

Receiving 503B office stock in Montana

Montana is the state where looking in the obvious place produces the wrong answer twice. There is no dedicated outsourcing-facility licence class, and the controlled-substances chapter uses a phrase that names a federal agency while appearing to name a state one.

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What Montana asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inHigh confidence

A wholesale distributor licence. Montana has no dedicated outsourcing-facility class, so the credential is the general one, at $240 for initial licence and annual renewal, with the manufacturer licence priced the same. An out-of-state wholesale distributor, third-party logistics provider, manufacturer or repackager may not do business in the state without it. Licensing runs through the Board of Pharmacy, which sits inside the Department of Labor and Industry.

Does your practice need a permit?High confidence

Only if it dispenses. Montana registers medical practitioners who dispense drugs, at $240 initially and $150 on renewal. A practice that administers rather than dispenses is in a different position, because the administration of a unit dose to a patient is expressly outside the prohibition the registration relieves.

Administer vs dispenseHigh confidence

This is the sharpest administer-versus-dispense line in the file, and it runs differently for each drug class. Non-controlled: a practitioner may dispense with registration. Controlled: a practitioner may not dispense at all unless engaged in the practice of pharmacy. Administering a unit dose sits outside both. The wholesale definition, separately, reaches supply to entities authorized to purchase, administer or dispense — so administration is inside the wholesale net even where it is outside the dispensing one.

Scheduled (controlled) stockHigh confidence

Montana waives its own registration for practitioners who hold the federal one — but the waiver says "other than pharmacies" in terms, so a pharmacy gets no such relief. Registration is location-based: a separate one is required at each principal place of business or professional practice.The controlled-substances chapter defines "Bureau" as the federal Drug Enforcement Administration within the United States Department of Justice. A reader who sees "department of justice" in that chapter and goes looking for a Montana Department of Justice registry will find nothing, because the registrar is the Board of Pharmacy.

How to check a facility’s credential before you order is set out in how to place an office-use order.

What this page does not establish

• This page takes no position on whether Montana permits or prohibits office use, because Montana has legislated neither way. The observation that its silence leans permissive is an inference from the structure of its definition of compounding, and it is offered as that rather than as a rule you can cite.
• The pending rulemaking described above is the live risk on this page. If it is adopted in the form proposed, Montana acquires a patient-specific requirement and a licensing rule aimed squarely at outsourcing facilities supplying prescribers, and most of this page changes. Whether it has since been adopted is worth checking before relying on anything here.
• One textual discrepancy is reported rather than resolved: legislation effective 1 October 2025 repealed several sections of the pharmacy chapter, and the board’s sterile products rule still lists two of the repealed sections as its implementing statutes. That is a flag about the citation, not a conclusion about the rule’s validity, which we are not in a position to reach.
• Montana’s rules are published through an application that serves no rule text to an automated request, so the rule quotations a reader might want to check independently have to be opened in a browser. This page cites the record for the rule in the state’s own rules library, which confirms the rule number, its name and that it is in force.
• We searched no case law, attorney-general opinions or declaratory rulings for this state, and search engines were unavailable when it was researched. Read nothing into that silence — it means we have not looked, not that nothing is there.